Skip to main content

Advertisement

SpringerLink
Log in

Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Enhanced glycolysis is a common trait of many types of human cancers. This study was to detect the expression pattern of three regulatory enzymes during glycolysis in esophageal squamous cell carcinoma (ESCC) and to investigate their correlation with patients’ outcome based on banked pathology material. A total of 141 surgically resected specimens of primary ESCC patients without prior treatments were retrospectively recruited from the First Affiliated Hospital of Wenzhou Medical College Hospital from 2007 to 2009. Expression of HK1, PFKB, and PKM2 in ESCC specimens was analyzed by immunohistochemical staining and Western blotting analysis. HK1-shRNA was used to knock down HK1 expression in ESCC cells, and the functional significance was assessed by CCK8 assay. It was found that the expression of two glycolytic enzymes, HK1 and PKM2, was associated with disease progression, invasion, and poor survival of patients with ESCC. Silence of HK1-inhibited cell proliferation in vitro and suppressed phospho-S6 kinase expression. Our findings suggest that activation of key enzymes in glycolysis might serve as potential therapeutic targets and/or prognostic factors for patients with ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.

    Article  PubMed  Google Scholar 

  2. Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179–83.

    Article  PubMed  Google Scholar 

  3. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417–22.

    Article  PubMed  CAS  Google Scholar 

  4. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9.

    Article  PubMed  CAS  Google Scholar 

  5. Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73–84.

    Google Scholar 

  6. Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625–9.

    Article  PubMed  Google Scholar 

  7. Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.

    PubMed  CAS  Google Scholar 

  8. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013;45:e45.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687–97.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18–27.

    PubMed  CAS  Google Scholar 

  12. Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–42.

    Article  PubMed  CAS  Google Scholar 

  13. Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14.

    Article  Google Scholar 

  14. Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle. 2013;12(19):3154–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510–5.

    Article  PubMed  CAS  Google Scholar 

  16. Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917–22.

    Article  PubMed  CAS  Google Scholar 

  17. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340–52.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014;53(1):75–87.

  19. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.

    Article  PubMed  CAS  Google Scholar 

  20. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7–8):1358–66.

    Article  PubMed  CAS  Google Scholar 

  21. Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.1007/s10238-013-0250-9.

  22. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.

    Article  PubMed  CAS  Google Scholar 

  23. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232.

    Article  PubMed  CAS  Google Scholar 

  24. Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355–60.

    PubMed  CAS  Google Scholar 

  25. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438–45.

    Article  CAS  Google Scholar 

  26. Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357–63.

    Article  PubMed  CAS  Google Scholar 

  27. Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang, China

    Wenfeng Li

  2. Department of Chemo-Radiotherapy, The People’s Hospital of Yinzhou District, Ningbo, 315000, Zhejiang, China

    Zhengyang Xu

  3. Department of Ultrosound, Fuzhou General Hospital of PLA, Fuzhou, 350025, Fujian, China

    Junfeng Hong

  4. Department of Dermatovenereology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang, China

    Yunsheng Xu

Authors
  1. Wenfeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhengyang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junfeng Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunsheng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yunsheng Xu.

Additional information

Wenfeng Li, Zhengyang Xu and Junfeng Hong have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W., Xu, Z., Hong, J. et al. Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival. Med Oncol 31, 118 (2014). https://doi.org/10.1007/s12032-014-0118-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0118-1

Keywords

Search

Navigation